Neurocrine Biosciences Inc (NBIX)
122.88
-2.63
(-2.10%)
USD |
NASDAQ |
Nov 14, 16:00
122.88
0.00 (0.00%)
After-Hours: 17:26
Neurocrine Biosciences Revenue (TTM): 2.243B for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 2.243B |
| June 30, 2024 | 2.120B |
| March 31, 2024 | 1.982B |
| December 31, 2023 | 1.887B |
| September 30, 2023 | 1.784B |
| June 30, 2023 | 1.673B |
| March 31, 2023 | 1.598B |
| December 31, 2022 | 1.489B |
| September 30, 2022 | 1.389B |
| June 30, 2022 | 1.297B |
| March 31, 2022 | 1.208B |
| December 31, 2021 | 1.134B |
| September 30, 2021 | 1.069B |
| June 30, 2021 | 1.032B |
| March 31, 2021 | 1.045B |
| December 31, 2020 | 1.046B |
| September 30, 2020 | 1.042B |
| June 30, 2020 | 1.006B |
| March 31, 2020 | 886.80M |
| December 31, 2019 | 788.10M |
| September 30, 2019 | 675.45M |
| June 30, 2019 | 605.11M |
| March 31, 2019 | 518.51M |
| December 31, 2018 | 451.20M |
| September 30, 2018 | 414.26M |
| Date | Value |
|---|---|
| June 30, 2018 | 323.28M |
| March 31, 2018 | 232.71M |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 | 2.919M |
| September 30, 2013 | 24.14M |
| June 30, 2013 | 32.76M |
| March 31, 2013 | 42.60M |
| December 31, 2012 | 53.14M |
| September 30, 2012 | 42.30M |
| June 30, 2012 | 74.58M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
788.10M
Minimum
Dec 2019
2.243B
Maximum
Sep 2024
1.386B
Average
1.252B
Median
Revenue (TTM) Benchmarks
| Repligen Corp | 602.35M |
| West Pharmaceutical Services Inc | 2.876B |
| Bruker Corp | 3.241B |
| The Cooper Companies Inc | 3.804B |
| Integra Lifesciences Holdings Corp | 1.565B |